Clinical assessment of fluorescence cystoscopy during transurethral bladder resection in superficial bladder cancer
✍ Scribed by Jichlinski, P. ;Wagnières, G. ;Forrer, M. ;Mizeret, J. ;Guillou, L. ;Oswald, M. ;Schmidlin, F. ;Graber, P. ;Van den Bergh, H. ;Leisinger, H. J.
- Publisher
- Springer
- Year
- 1997
- Tongue
- English
- Weight
- 385 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Difluoromethylornithine (DFMO) is a promising chemopreventive agent which is excreted unchanged in the urine, is active in vivo against superficial bladder cancer in animal tumor model systems, and has cytotoxic activity in viffo against superficial bladder cancer cells. Thus, DFMO may be particular
Several postoperative adjuvant therapeutic modalities have been adopted in attempts to reduce the recurrence rate of superficial bladder cancer. However, no definite conclusions on the effectiveness of intravesical chemoprophylaxis have been reached. A randomized clinical study on intravesical chemo
This paper examines the amount of variation among centres and estimates the overall e!ect of therapy in a multi-centre cancer clinical trial with censored failure time data. To investigate the centre e!ects, the variation in the treatment e!ect must be taken into consideration in addition to the var